Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Tumor Infiltrating Lymphocytes Market Growth Potential: How Will Market Size Shift Through 2030?
The tumor infiltrating lymphocytes market has seen significant expansion in recent years. It is anticipated to expand from $12.05 billion in 2025 to $13.75 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.2%. The growth observed in previous periods can be attributed to factors such as the increasing prevalence of cancer, advancements in immunotherapy research, a growing awareness of personalized medicine, the early successes of adoptive cell therapies, and collaborations forged between research institutions and biotech companies.
The market size for tumor infiltrating lymphocytes is anticipated to experience substantial growth in the upcoming years. It is projected to expand to $23.25 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.0%. This expansion during the forecast period is driven by factors such as the increasing adoption of tumor infiltrating lymphocytes therapies, the growth of cGMP-compliant manufacturing facilities, the integration of AI in optimizing cell therapy processes, a surge in strategic collaborations between pharmaceutical and biotechnology firms, and regulatory green lights for innovative T-cell therapies. Significant trends observed within this period include the progression of personalized cell therapy, advanced ex vivo T-cell expansion techniques, combined immunotherapy strategies, modification of the tumor microenvironment, and sophisticated cell storage and cryopreservation methods.
Get A Free Sample Report With In-Depth Market Insights:
Tumor Infiltrating Lymphocytes Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The growing number of individuals diagnosed with cancer is projected to stimulate the expansion of the tumor infiltrated lymphocytes (TIL) market moving forward. Cancer is defined as a condition where certain bodily cells multiply without control and disseminate to other areas, leading to various health issues, some of which can be fatal. Tumor-infiltrating lymphocytes are a specific type of immune cell adept at recognizing and eliminating cancer cells. These lymphocytes are extracted from a patient’s tumor, massively expanded in a laboratory environment, and then re-infused into the patient to bolster the immune system’s capacity to destroy cancer cells. For instance, in August 2024, a report published by the Australian Institute of Health and Welfare, an Australian-based national agency for information and statistics on Australia’s health and welfare, projected that by 2034, Australia would face approximately 209,000 new cancer diagnoses. This marks a significant increase from the estimated 169,000 cases expected in 2024, reflecting the combined impact of population growth and increasing cancer incidence rates. Additionally, it is anticipated that in 2024, cancer will contribute to about 3 out of every 10 deaths in the country. Hence, the increasing prevalence of cancer patients will drive the tumor infiltrated lymphocyte market.
Tumor Infiltrating Lymphocytes Market Segments: Where Is Growth Concentrated?
The tumor infiltrating lymphocytes market covered in this report is segmented –
1) By Anatomy: CD3, CD8, CD16, CD56, CD4, CD57, FOXP3
2) By Component: T-Cells, Natural Killer Cells
3) By Application: Melanoma, Cervical Cancer, Ovarian Cancer, Other Applications
4) By End-User: Hospitals, Cancer Research Centers, Clinics
Tumor Infiltrating Lymphocytes Market Innovation Trends Shaping Future Development
Leading companies in the tumor-infiltrating lymphocyte market are adopting a strategic partnership approach, aiming to develop innovative treatments that control gene editing. Strategic partnerships involve companies leveraging each other’s strengths and resources to achieve mutual benefits and success. For instance, in February 2023, Moderna, a US-based pharmaceutical and biotechnology company, entered into a strategic collaboration with Life Edit Therapeutics, a US-based next-generation genome editing company, to accelerate the development of novel in vivo gene editing therapies. This partnership seeks to combine Moderna’s mRNA technology with Life Edit’s proprietary genome editing platform to create more effective and precise therapies for various diseases, including cancer and genetic disorders. The collaboration reflects a growing trend in the biopharmaceutical industry to integrate innovative technologies for advanced therapeutic solutions.
Tumor Infiltrating Lymphocytes Market Key Participants And Competitive Landscape
Major companies operating in the tumor infiltrating lymphocytes market are Novartis AG, Pfizer Inc., Precision BioScience Inc., TCR2 Therapeutics Inc., Merck KGaA, Autolus Therapeutics PLC., Eli Lilly and Company, Oxford Biomedica PLC., Unum Therapeutics Inc., Amgen Inc., Gilead Sciences Inc., Sorrento Therapeutics Inc., TILT Biotherapeutics Ltd., Iovance Biotherapeutics Inc., Adaptimmune Therapeutics plc, Atara Biotherapeutics Inc., BioNTech SE, CARsgen Therapeutics Ltd., Cellectis S.A., Celyad Oncology SA, CRISPR Therapeutics AG, Intellia Therapeutics Inc., MaxCyte Inc.
View The Full Tumor Infiltrating Lymphocytes Market Report:
Tumor Infiltrating Lymphocytes Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the tumor infiltrating lymphocytes market in 2025. The regions covered in the tumor infiltrating lymphocytes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
